RT Journal Article SR Electronic T1 Awareness and Agreement with Neurofibromatosis Care Guidelines among Neurofibromatosis Specialists JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.06.16.21259047 DO 10.1101/2021.06.16.21259047 A1 Vanessa L. Merker A1 Pamela Knight A1 Heather B. Radtke A1 Kaleb Yohay A1 Nicole J. Ullrich A1 Scott R. Plotkin A1 Justin T. Jordan YR 2021 UL http://medrxiv.org/content/early/2021/08/12/2021.06.16.21259047.abstract AB Introduction Given the wide range of neurofibromatoses (NF) symptoms and medical specialties involved in NF care, we sought to evaluate the level of awareness of, and agreement with, published NF clinical guidelines among United States NF specialists.Methods An anonymous, cross-sectional online survey was distributed to attendees of a large NF research conference. Respondents self-reported demographics, practice characteristics, awareness of seven NF guideline publications, and level of agreement with up to 40 individual guidelines using a 5-point Likert scale. We calculated the proportion of guidelines that each clinician rated “strongly agree”, and assessed for differences in guideline awareness and agreement by respondent characteristics.Results Sixty-three clinicians (49% female; 80% academic practice) across >8 medical specialties completed the survey. Awareness of each guideline publication ranged from 53%-79% of respondents; specialists had higher awareness of publications endorsed by their medical professional organization (p<0.05). The proportion of respondents who “strongly agree” with individual guidelines ranged from 17%-83%; for 16 guidelines, less than 50% of respondents “strongly agree”. There were no significant differences in overall agreement with guidelines based on clinicians’ gender, race, specialty, years in practice, practice type (academic/private practice/other), practice location (urban/suburban/rural), or involvement in NF research (p>0.05 for all).Conclusions We identified wide variability in both awareness of, and agreement with, published NF care guidelines among NF experts. Future efforts should focus on evidence-based, consensus-driven methods to update and disseminate guidelines across this multi-specialty group. Patients and caregivers should also be consulted to anticipate barriers to accessing and implementing guideline-driven care.Competing Interest StatementThe authors report no conflicts of interest pertinent to this manuscript. Financial disclosures for authors include the following: Dr. Merker reports consulting income from the Neurofibromatosis Network. Ms. Knight and Ms. Radtke are employees of the Childrens Tumor Foundation. Dr. Yohay reports consulting income from AstraZeneca and receives royalties from Wolters Kluwer. Dr. Ullrich reports patents held with University of Alabama Research Foundation; royalties from UpToDate; honoraria for speaking with AstraZeneca, and research support from the Childrens Tumor Foundation, Department of Defense and National Institutes of Health. Dr. Plotkin is co-founder of NFlection Therapeutics, Inc. and of NF2 Therapeutics, Inc and a consultant for AstraZeneca and for SonalaSense. Dr. Jordan receives royalties from Elsevier and reports consulting income from Navio Theragnostics, Health2047, and from CereXis.Clinical TrialPaper reports a prospective, cross-sectional survey, and so did not require a trial ID as it was not a clinical trial.Funding StatementThis study was supported in part by the Childrens Tumor Foundation. Preparation of this manuscript was supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Health Services Research, the Center for Healthcare Organization and Implementation Research (CHOIR), and the VA Bedford Healthcare System. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed by the Mass General Brigham Institutional Review Board and was deemed to meet criteria for exemption. Participation in the survey was voluntary and anonymous. Participants read a short fact sheet about the study and indicated their consent to participate by completing the survey.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWhile the survey was anonymous, there is a risk of identification from unique combinations of multiple demographic factors in this small group of specialists. For this reason, the full dataset is not publicly available. De-identified data is available upon reasonable request from the corresponding author.